-
Mashup Score: 1STARTAR: AR inhibition + ADT + apalutamide + RT + docetaxel for salvage in PSA recurrent PC after RP - 9 month(s) ago
Andrew J. Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, the primary analysis of the Phase II STARTAR (NCT03311555) salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP). The primary endpoint was 36-month progression-free survival (PFS). Results from the trial demonstrated that the 36-month PFS rate was 72%, with durable remissions beyond historical controls. Most patients completed the planned treatment, achieved undetectable PSA levels, and experienced manageable adverse events. This study suggests that intensifying systemic treatments in the non-metastatic hormone-sensitive but high-risk salvage setting may be feasible and effective in reducing cancer progression. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are ow
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Current developments in FGFR inhibitors for urothelial cancer - 9 month(s) ago
Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, gives an overview of FGFR inhibition in urothelial cancer. With the exception of erdafitinib, relatively few FGFR inhibitors including infigratinib and rogaratinib have shown success in clinical trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, describes the rationale and trial design of the EV-103 trial (NCT03288545), which assessed enfortumab vedotin (EV), an antibody-drug conjugate (ACD), and pembrolizumab in patients with first-line cisplatin-ineligible locally advanced or metastatic urothelial carcinoma. The combination of EV and pembrolizumab had encouraging antitumor activity and a manageable safety profile in cohort A, which had a dose escalation component, and cohort K. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Advancements in systemic therapy for kidney cancer: implications for treatment decision-making - 9 month(s) ago
Shawn Dason, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, highlights the significant advancements in systemic therapy for kidney cancer in recent years, leading to improved outcomes compared to the past. While surgical approaches like nephrectomy and metastasectomy haven’t seen major breakthroughs, it’s essential to recognize the changing landscape and consider the latest data when making treatment decisions. Late-breaking abstracts of Phase III trials have shown promising long-term efficacy with systemic therapies. Dr Dason emphasizes the incorporation of the evolving knowledge of systemic treatments into the overall management of kidney cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Interim results from ARCADIA trial: cabozantinib plus durvalumab in advanced urothelial carcinoma - 10 month(s) ago
Patrizia Giannatempo, MD, Foundation IRCCS National Cancer Institute, Milan, Italy, discusses the Phase II ARCADIA (NCT03824691) trial investigating the combination…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 10 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0HRQoL and pain outcomes in mCRPC: abi + ala vs abi + pbo in PROpel - 10 month(s) ago
Andrew J. Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, shares the health-related quality of life (HRQoL) and pain outcomes…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1VJOncology – The video journal of oncology - 10 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Dr. Emamekhoo explains the background of the cancer drug shortage - 10 month(s) ago
The shortage has been affecting the treatment of patients with genitourinary cancers, including bladder cancer.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 10 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
🎥@AarmstrongDuke of @DukeCancer presents STARTAR trial findings! Apalutamide and RT followed by docetaxel show promising 36-month PFS rates of 72% in recurrent prostate cancer after radical prostatectomy: ➡️https://t.co/BMqvcZ7QJ6⬅️ #ASCO23 #PCSM #UroOnc #UroSoMe